{"symbol":"BMY","fiscalQuarter":"Q3-2016","reportDate":"2016-10-27","reportTime":"BMO","status":"reported","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q3-2016","postBrief":{"headline":"Bristol Myers Squibb Beats on EPS, Stock Up 5.42%","keyNumbers":[{"metric":"EPS","actual":"$0.77","expected":"N/A","surprise":"+18.64%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["The company is pleased with the EPS performance this quarter.","Management highlighted ongoing efforts to drive growth in key therapeutic areas."],"summary":"Overall, management expressed satisfaction with the earnings beat. They emphasized their commitment to maintaining momentum in their product pipeline."},"guidanceChanges":{"summary":"No guidance updates were provided during the earnings call.","changes":[]},"whatItMeans":"Bristol Myers Squibb's strong EPS performance indicates effective cost management and potentially robust product sales. The stock's 5.42% increase reflects investor confidence following the earnings beat. However, the lack of revenue data and guidance leaves some uncertainty about future performance.","metaDescription":"Bristol Myers Squibb (BMY) Q3 2016 earnings: EPS beat by 18.64%. Stock up 5.42%. Full breakdown."}}